Plus Therapeutics (NASDAQ:PSTV) Releases Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:PSTV) announced its quarterly earnings results on Thursday. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16), Zacks reports. The company had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.19 million.

Plus Therapeutics Stock Down 23.7 %

Shares of PSTV stock opened at $1.16 on Friday. The stock’s 50-day moving average price is $1.11 and its 200 day moving average price is $1.24. The stock has a market capitalization of $6.84 million, a PE ratio of -0.46 and a beta of 0.73. Plus Therapeutics has a 52-week low of $0.24 and a 52-week high of $2.67.

Analysts Set New Price Targets

PSTV has been the topic of several research reports. Ascendiant Capital Markets dropped their price objective on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th. HC Wainwright dropped their price target on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating on the stock in a research note on Friday. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Plus Therapeutics in a research note on Friday.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.